[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 1,633
    Citations 0
    Research Letter
    December 20, 2019

    Long-term Outcome of Implantable Cardioverter/Defibrillator Lead Failure

    Author Affiliations
    • 1Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    • 2Landspitali–The National University Hospital of Iceland, Reykjavik, Iceland
    JAMA Intern Med. 2020;180(2):322-324. doi:10.1001/jamainternmed.2019.4717

    Implantable cardioverter/defibrillators (ICDs) are established for treatment and prevention of sudden death from ventricular arrhythmias.1 An ICD system consists of a generator and a lead. The design of the ICD leads differs between manufacturers, some of which have had higher lead failure rates than others.2

    The Riata defibrillator leads, manufactured by St Jude Medical Inc, were introduced in 2002. They had a novel silicone insulation design that was found to be prone to a specific insulation abrasion, characterized by externalization of the conductor (EC). These leads were designated to a class I recall by the US Food and Drug Administration in late 2011 owing to significant rates of lead failure and an insulation defect, posing significant management challenges.

    ×